Prefrontal Energy Failure as the Unifying Substrate of ADHD-Like Executive Dysfunction in ME/CFS
The prefrontal cortex (PFC) governs executive functions: working memory, impulse inhibition, emotional regulation, attentional control, planning, and the ability to pause and choose a response rather than react. It is the most metabolically expensive region in the human brain. Under ATP scarcity, it is the first brain system to degrade. This single fact unifies the scattered evidence across this document — PFC vulnerability (Brain Energy Metabolism: Cross-Disease Convergent Framework), catecholamine inverted-U pharmacology (Medication Response Reference: From Drug Response to Mechanism Identification), energy triage hierarchy (energy triage hierarchy), same-root ADHD hypothesis (ADHD and ME/CFS as Same-Root Etiology — Inflammation-Driven Energy Failure), and epidemiological ADHD-ME/CFS overlap — into one mechanistic chain: mitochondrial energy failure → selective prefrontal ATP deficit → executive dysfunction → ADHD-like clinical phenotype.
1 The PFC as the Brain’s Metabolic Bottleneck
The PFC consumes disproportionately more glucose and oxygen per gram of tissue than any other cortical region. Persistent-firing mechanisms underlying working memory — sustained neural activity without external input — require continuous Na+/K+-ATPase pump operation, making them exquisitely sensitive to ATP availability (Constantinidis et al. 2018). Functional neuroimaging consistently shows that cognitive tasks engaging the PFC produce the largest metabolic signal in the brain. This is not a design flaw — it is the price of higher cognition. The consequence: any condition that reduces cerebral ATP delivery or production will impair PFC function before any other brain function, and will impair executive function before memory, motor skills, or vital functions.
The energy triage hierarchy (energy triage hierarchy) formalizes this: Tier 5 (executive function) requires 85% of normal energy budget to operate, Tier 6 (complex cognition) requires 95%, while Tier 1 (brainstem vital functions) requires only 30%. In ME/CFS, available CNS energy falls below the Tier 5 threshold but above the Tier 1–3 thresholds. The clinical result is exactly what patients report: preserved vital functions and basic sensory-motor processing, but impaired planning, impulse control, emotional regulation, sustained attention, and task-switching — the core ADHD symptom cluster.
2 Evidence Convegence: Five Independent Lines
Line 1 — Cerebrovascular demand failure. Ninety-one percent of ME/CFS patients with normal resting cerebral blood flow show abnormal CBF reduction during orthostatic challenge Selective Energy Dysfunction. The PFC is the region most sensitive to perfusion drops because its metabolic rate is highest. Even modest CBF reduction during upright posture preferentially starves the PFC, producing postural cognitive impairment — “brain fog that worsens when standing” — as a predictable hemodynamic consequence of PFC metabolic vulnerability.
Line 2 — Brain glucose hypometabolism. FDG-PET imaging documents regional brain glucose hypometabolism in ME/CFS (Siessmeier et al. 2003) (Van Der Gucht et al. 2017). PFC-specific glucose metabolism has not been isolated in ME/CFS studies, but Zametkin et al. (1990) showed 8.1% lower global cerebral glucose metabolism in ADHD adults, with the largest reductions in superior prefrontal cortex (Zametkin et al. 1990). The ADHD brain is a PFC-hypometabolic brain. If ME/CFS produces cerebral hypometabolism, the affected regions should overlap with those identified in ADHD — and the existing ME/CFS FDG-PET data, though not PFC-specific, are consistent with this prediction.
Line 3 — Cerebral creatine depletion. Godlewska et al. (2024) documented brain creatine deficiency in ME/CFS by 7T MRS, with significant depletion in dorsolateral prefrontal cortex (+2.9% recovery after supplementation) and pregenual anterior cingulate (+8.3%) (Godlewska et al. 2024). The PCr shuttle is the brain’s rapid ATP buffer — essential for the high burst demands of working memory and executive function. PFC creatine depletion means the PFC cannot buffer ATP demand spikes, directly predicting: impaired sustained attention (the PFC runs out of ATP mid-task), impaired working memory (insufficient PCr for persistent firing), and impaired impulse inhibition (the ATP-expensive inhibitory networks fail first).
Line 4 — Dopaminergic-noradrenergic deficit. The Walitt et al. (2024) NIH deep phenotyping study documented reduced CSF catecholamines in ME/CFS (Walitt et al. 2024). PFC D1 dopamine receptors and α2A noradrenergic receptors operate on an inverted-U dose-response curve: too little catecholamine tone impairs executive function via insufficient receptor activation, while too much impairs it via noise amplification (Arnsten 2011) (Cools and D’Esposito 2011). The ME/CFS pattern — 77.1% of patients report stimulant benefit for brain fog (Eckey et al. 2025) — is consistent with left-arm (suboptimal) PFC catecholamine tone, where low ATP availability compounds low transmitter availability to doubly impair executive circuits. The ADHD-ME/CFS pharmacological convergence — both conditions respond to methylphenidate, atomoxetine, and guanfacine — is not coincidental; it reflects the same PFC circuit inadequately fueled by the same underlying energy-metabolic deficit.
Line 5 — Epidemiological gradient. Childhood ADHD is present in 29.7% of adult CFS patients (Sáez-Francàs et al. 2012). ADHD traits at age 9 predict 2× chronic fatigue risk at age 18, mediated by IL-6 (Quadt et al. 2024). This is not merely comorbidity — it is a dose-response gradient consistent with a shared biological substrate: patients starting with lower PFC metabolic reserve (ADHD) are the first to cross the ME/CFS clinical threshold when an additional metabolic hit (infection, inflammation, trauma) further reduces CNS energy availability.
The unification. All five lines converge on a single geometric fact: the PFC is the brain region with the highest ATP demand per gram of tissue. This means PFC function is the first to degrade under energy scarcity, regardless of whether the scarcity arises from reduced cerebral perfusion (Line 1), impaired glucose metabolism (Line 2), depleted creatine buffering (Line 3), inadequate catecholamine tone (Line 4), or inherited lower metabolic baseline (Line 5). Each line is an independent path to the same endpoint — PFC energy failure — and a given patient may have one, several, or all of these pathologies superimposed. The ADHD-like executive dysfunction observed in ME/CFS is not a separate comorbidity requiring a separate diagnosis. It is the necessary and predictable consequence of any condition that reduces the brain’s ATP budget below the Tier 5 threshold. The question is not “does this patient have ADHD?” but “why would a brain with inadequate energy supply to the PFC produce anything other than ADHD-like executive dysfunction?”
Clinical implication. This framework predicts that executive function severity should correlate with objective measures of cerebral energy status — MRS PCr:ATP ratio, FDG-PET PFC glucose uptake, and CBF during orthostatic challenge — and that treatments improving cerebral energy delivery (ketogenic therapy, creatine supplementation, cerebral vasodilators) should improve executive function in proportion to the degree of baseline PFC energy deficit. It also predicts that stimulant response in ME/CFS (77.1% for brain fog (Eckey et al. 2025)) reflects temporary pharmacological compensation for PFC energy failure — not a distinct ADHD diagnosis — and that stimulant efficacy should correlate with the degree of PFC metabolic abnormality rather than with ADHD history.
A double-blind, placebo-controlled, counterbalanced three-way crossover trial in 21 adolescents with ADHD compared a high-dose L-theanine-caffeine combination against methylphenidate and placebo on a visual selective-attention task (Nawarathna et al. 2026). Both the combination and methylphenidate reduced false alarms (target–distractor discrimination errors, P = 0.038 and P = 0.035) and increased P3b event-related-potential amplitude while decreasing P3b latency (P < 0.05) — a shared enhancement of attentional resource allocation and of the neural speed of target evaluation. However, only methylphenidate improved behavioral reaction time (43.89 ms, P = 0.018), while the L-theanine-caffeine combination did not. L-theanine-caffeine engages adenosine (A1/A2A antagonism by caffeine) and glutamatergic/GABAergic (theanine) mechanisms, whereas methylphenidate blocks the dopamine transporter. The pattern is not a clean selection-vs-speed dissociation: P3b latency is itself a processing-speed index, and the non-dopaminergic combination improved it even though it did not shorten behavioral reaction time. So the divergence is specifically between two speed measures — a neural speed index (P3b latency) improved in both conditions, while behavioral reaction time improved only with methylphenidate. This complicates any claim that only the dopaminergic route governs speed. The result is further qualified by the fact that the same trial’s components act through overlapping systems: functional imaging shows caffeine and methylphenidate both enhance memory through a shared fronto-parietal default-mode network decoupling (Becker et al. 2022), and L-theanine alone improved choice reaction time (SMD 0.51) in a 31-RCT meta-analysis of healthy adults (Gerolymos et al. 2026) — a non-dopaminergic behavioral speed effect. The present finding therefore rests on a single small trial from one research group (n=21, not independently replicated) (Nawarathna et al. 2026) (Kahathuduwa et al. 2020) and does not establish that attention selection and processing speed are governed by separable neurochemical routes; it connects to the separate speculation that elevated A2A receptor density underlies ME/CFS’s anomalous caffeine responses Elevated A2A Receptor Density Underlies ME/CFS Caffeine Paradox. Falsifiability: a pre-registered, adequately powered ADHD crossover (n ≈ 60+) demonstrating that an L-theanine-caffeine combination also shortens behavioral reaction time would confirm that the RT null in this trial was an artifact of underpowering rather than a true route difference; if instead a larger trial replicates the RT null while again improving P3b latency, it would support a dissociation between motor/premotor speed (dopamine-sensitive) and perceptual speed (not exclusively dopamine-sensitive). Three further nulls bound the claim: L-theanine is null for fatigue across 31 RCTs (Gerolymos et al. 2026); caffeine shows no association with ME/CFS (only an inverse association with severe fatigue, not the syndrome) (Palacios et al. 2023); and caffeine monotherapy shows no ADHD benefit — the effect is combination-dependent (Al Shahab et al. 2025). The hypothesis that adenosine-receptor antagonism “masks rather than restores” the underlying deficit is equally consistent with the data, so the adenosine route’s causal role in ME/CFS is currently unsupported and probably null — the default assumption is no causal role until a direct test shows otherwise. Consequence: in ME/CFS, where PFC catecholamine tone is suboptimal (77.1% report stimulant benefit (Eckey et al. 2025)), this trial cautions against assuming that a nutraceutical that improves one attention measure will improve them all — P3b latency improved while behavioral reaction time did not — but L-theanine is null for fatigue (Gerolymos et al. 2026), caffeine carries withdrawal-fatigue and tolerance harm (Carbone et al. 2025) and no ME/CFS association (Palacios et al. 2023), and the entire edifice rests on a single small trial from one research group (n=21, acute single-dose, ADHD cohort, no ME/CFS data, not independently replicated) (Nawarathna et al. 2026) (Kahathuduwa et al. 2020). It therefore remains cross-disease mechanism context, NOT an ME/CFS treatment. (Raw certainty 0.55, ADHD disease-model population → discounted to 0.41; severity applicability unknown — study cohort not stratified by severity; evidence: general-population/ADHD crossover RCT, not ME/CFS-specific; origin: literature integration.)
The L-theanine-caffeine trial offers a natural experiment for the ME/CFS PFC-energy question, but it does not yield a single clean prediction. On this task, errors index target-distractor discrimination while reaction time indexes speed of deployment. One reading — that the non-dopaminergic (adenosine/glutamatergic) selection route is comparatively spared while the dopaminergic speed route fails — would predict a “slow-but-accurate” ME/CFS phenotype: preserved error rates with selectively slowed reaction time (Nawarathna et al. 2026). But the section’s own energy-triage framework points the other way: because the PFC’s ATP-expensive inhibitory networks fail first under energy scarcity (Tier 5), a selective-attention task might instead produce increased false alarms (a commission-error/accuracy deficit) alongside slowed responses — a “slow-and-inaccurate” phenotype, the opposite dissociation. Which pattern ME/CFS patients show is an open empirical question, and both outcomes are informative: preserved accuracy with selective speed loss would support a comparatively spared selection route; an accuracy deficit would support the framework’s prediction that inhibition fails before discrimination. Falsifiability: an objective selective-attention task in ME/CFS (vs. matched healthy and depressed controls) that shows proportionally impaired errors and reaction time, or normal reaction time, falsifies the “slow-but-accurate” reading; preserved accuracy with selectively slowed reaction time supports it; an accuracy deficit with slowed responses supports the impulse-inhibition-first reading. The three outcomes are mutually exclusive and each is testable. Consequence: whichever pattern replicates, it gives clinicians and researchers an objective cognitive-behavioral readout of the PFC energy/catecholamine state that is cheaper than imaging or EEG, and it sharpens the distinction between ME/CFS brain fog and the uniformly-slowed cognition of primary depression — but both candidate phenotypes are currently predictions from one ADHD crossover trial, not established ME/CFS findings. (Certainty: 0.20; evidence: cross-disease extrapolation from a single ADHD trial — mechanistic, not ME/CFS-specific; severity applicability unknown; origin: brainstorm.)